Drug Discovery World

AUGUST 29, 2024

Now, with HT-SPR, researchers have the ability to screen entire antibody and small molecule libraries, along with characterising epitopes, so there is way more data available at the earliest stages of drug discovery than ever before.”

Small Molecule 147

Small Molecule Drugs Protein Expression Assay Development 147

Drug Discovery World

SEPTEMBER 29, 2022

During a 2021 webinar on optimising assay development for hit identification, a survey asked over 50 drug discovery scientists, “Which goal is the highest priority when developing a drug discovery assay?”. protein-protein or small molecule-target interactions). Opportunities, options, and outsourcing.

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130

Sygnature Discovery

JUNE 17, 2024

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.

Biophysical Assays 52

Biophysical Assays Screening Hits Fragment Screening Assay Development 52

Elrig

APRIL 29, 2024

Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59